Asia Pacific Preimplantation Genetic Diagnosis Market Size Study, by Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others) and Country Forecasts 2022-2032

Asia Pacific Preimplantation Genetic Diagnosis Market Size Study, by Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others) and Country Forecasts 2022-2032

Asia Pacific Preimplantation Genetic Diagnosis Market is valued at approximately USD 16.59 million in 2023 and is anticipated to grow with a healthy growth rate of more than 12.69% over the forecast period 2024-2032. Preimplantation Genetic Diagnosis (PGD) is an advanced reproductive technique used with In Vitro Fertilization (IVF) to screen embryos for genetic disorders before implantation. This process increases the likelihood of a healthy child for couples at risk of passing on genetic disorders. IVF involves hormonal stimulation of the ovaries, egg collection, and fertilization in a lab. Embryos are developed to the blastocyst stage, biopsied, and examined for genetic defects. Healthy embryos are selected for uterine transfer. PGD reduces genetic disorder transmission, enhances IVF success rates, and raises ethical concerns about embryo selection and genetic confidentiality. It is particularly beneficial for couples with a history of genetic disorders, recurrent miscarriages, or fertility issues. The Asia Pacific Preimplantation Genetic Diagnosis Market is growing due to increasing awareness of genetic disorders and the benefits of early detection. Rising infertility rates, acceptance of assisted reproductive technologies, and technological advancements in genetic testing boost PGD's accuracy and accessibility. Supportive government initiatives and expanding healthcare infrastructure further drive market growth.

The Asia Pacific Preimplantation Genetic Diagnosis (PGD) market is driven by the increasing prevalence of genetic disorders, rising awareness and acceptance of genetic testing, advancements in genomic technologies, and supportive regulatory frameworks are significant drivers. Additionally, the growing number of fertility clinics and the rising demand for IVF procedures contribute to market growth. A qualitative description of one of these drivers is the advancements in genomic technologies, which have significantly enhanced the accuracy and efficiency of PGD, enabling the identification of genetic abnormalities with greater precision and reducing the risk of hereditary diseases. However, the market faces several restraints. High costs associated with PGD procedures, ethical concerns, and regulatory challenges in certain countries may hinder market expansion. Furthermore, limited awareness and accessibility in developing regions pose additional challenges.

The key Countries considered for the Asia Pacific Preimplantation Genetic Diagnosis market study include China, India, Japan, South Korea, Australia and the Rest of Asia Pacific. China is the dominating region in terms of revenue in the Asia Pacific Preimplantation Genetic Diagnosis (PGD) Market. The country has a large population, which leads to a higher number of couples seeking fertility treatments and genetic testing. There is an increasing incidence of genetic disorders, which amplifies the demand for PGD services. The Chinese government’s supportive policies and substantial investments in healthcare infrastructure and genetic research further boost the market. Additionally, China has made significant advancements in genomic technologies, enhancing the accuracy and efficiency of PGD procedures. On the other hand, the market in India is expected to develop at the fastest rate over the forecast period.

Major market players included in this report are:
BGI Genomics Co., Ltd.
Berry Genomics Co., Ltd.
Shanghai GenePharma Co., Ltd.
Takara Bio Inc.
Sysmex Corporation
Fujifilm Holdings Corporation
Seegene Inc.
Macrogen Inc.
Monash IVF Group Limited
MedGenome Labs Ltd.

The detailed segments and sub-segments of the market are explained below:

By Test Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single Gene Disorders
HLA Typing
Gender selection
Others
By Region:
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.